Review



af909 psd95 mab rabbit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    R&D Systems af909 psd95 mab rabbit
    List of antibodies used in the study
    Af909 Psd95 Mab Rabbit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 171 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/af909 psd95 mab rabbit/product/R&D Systems
    Average 99 stars, based on 171 article reviews
    af909 psd95 mab rabbit - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease"

    Article Title: Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

    Journal: Brain

    doi: 10.1093/brain/awz364

    List of antibodies used in the study
    Figure Legend Snippet: List of antibodies used in the study

    Techniques Used: Flow Cytometry

    Cognitive preservation and restricted pathology following adoptive transfer of a CD115+ ACE10 monocyte subset in AD+ mice transgenic mice. (A–C) Schematic representation of experimental procedure and treatment groups. (A) CD115+ monocytes (MoBM) were isolated from the bone marrow of GFP+ donor mice and enriched by MACS microbeads and an anti-CD115 antibody column sorting procedure. (B) MoBM were then intravenously (i.v.) injected into the tail vein of AD+ recipient mice (n = 8 mice/group, all males). (C) Additional control groups included naïve wild-type (WT) mice and AD+ mice injected with PBS (n = 7 mice/group, all males). (D) Schematic timeline of the in vivo preclinical experiment. Pre-symptomatic AD+ mice exhibiting neuropathology at 8 months of age received monthly injections of 5–6 million GFP+MoWT or GFP+MoACE10 or PBS for 3 months (immunization regimen indicated by green arrows). At 11 months, mice underwent behavioural tests followed by tissue collection and analysis when 12 months of age. (E and F) Open field test in all AD+ treatment and naïve wild-type groups measuring: (E) ambulatory and (F) rearing activity. (G–K) Cognitive functions assessed by the Barnes maze test in both monocyte-treated groups as compared to the control PBS-injected group and naïve cognitively normal wild-type group (n = 6–8 mice/group). Incorrect entries (errors) for the following: (G) acquisition-training phase (Days 1–4), (H) memory retention (Day 7), (I) reversal phase (Days 8 or 9), and (J and K) memory test at Day 9. (J) Errors and (K) escape latency (s). (L) Quantitative IHC analysis of 6E10+ amyloid-β plaque areas in the hippocampus (HC), cingulate cortex (CC), and total brain in MoWT- and MoACE10-treated versus PBS-injected AD+ mice (n = 7–8 mice/group). (M) CAA score assessed as vascular Thio-S+ in AD+ mice (n = 6–8 mice/group). Data from an individual mouse as well as group mean ± SEM are shown. (N) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and postsynaptic (PSD95+) areas in MoACE10-treated mice compared to PBS-injected control AD+ and naïve wild-type mice (n = 6–8 mice/group). Data from individual mice, lower and upper quartiles (as lower and upper horizontal lines in box), median (midline within box), and minimum/maximum values (whiskers), are shown. Percentage increase and decrease compared to control groups are shown in green. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s post-test. Significance between two-groups by unpaired two-tailed Student t-test. IR = immunoreactive.
    Figure Legend Snippet: Cognitive preservation and restricted pathology following adoptive transfer of a CD115+ ACE10 monocyte subset in AD+ mice transgenic mice. (A–C) Schematic representation of experimental procedure and treatment groups. (A) CD115+ monocytes (MoBM) were isolated from the bone marrow of GFP+ donor mice and enriched by MACS microbeads and an anti-CD115 antibody column sorting procedure. (B) MoBM were then intravenously (i.v.) injected into the tail vein of AD+ recipient mice (n = 8 mice/group, all males). (C) Additional control groups included naïve wild-type (WT) mice and AD+ mice injected with PBS (n = 7 mice/group, all males). (D) Schematic timeline of the in vivo preclinical experiment. Pre-symptomatic AD+ mice exhibiting neuropathology at 8 months of age received monthly injections of 5–6 million GFP+MoWT or GFP+MoACE10 or PBS for 3 months (immunization regimen indicated by green arrows). At 11 months, mice underwent behavioural tests followed by tissue collection and analysis when 12 months of age. (E and F) Open field test in all AD+ treatment and naïve wild-type groups measuring: (E) ambulatory and (F) rearing activity. (G–K) Cognitive functions assessed by the Barnes maze test in both monocyte-treated groups as compared to the control PBS-injected group and naïve cognitively normal wild-type group (n = 6–8 mice/group). Incorrect entries (errors) for the following: (G) acquisition-training phase (Days 1–4), (H) memory retention (Day 7), (I) reversal phase (Days 8 or 9), and (J and K) memory test at Day 9. (J) Errors and (K) escape latency (s). (L) Quantitative IHC analysis of 6E10+ amyloid-β plaque areas in the hippocampus (HC), cingulate cortex (CC), and total brain in MoWT- and MoACE10-treated versus PBS-injected AD+ mice (n = 7–8 mice/group). (M) CAA score assessed as vascular Thio-S+ in AD+ mice (n = 6–8 mice/group). Data from an individual mouse as well as group mean ± SEM are shown. (N) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and postsynaptic (PSD95+) areas in MoACE10-treated mice compared to PBS-injected control AD+ and naïve wild-type mice (n = 6–8 mice/group). Data from individual mice, lower and upper quartiles (as lower and upper horizontal lines in box), median (midline within box), and minimum/maximum values (whiskers), are shown. Percentage increase and decrease compared to control groups are shown in green. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s post-test. Significance between two-groups by unpaired two-tailed Student t-test. IR = immunoreactive.

    Techniques Used: Preserving, Adoptive Transfer Assay, Transgenic Assay, Isolation, Injection, Control, In Vivo, Activity Assay, Two Tailed Test



    Similar Products

    af909 psd95 mab rabbit  (R&D Systems)
    99
    R&D Systems af909 psd95 mab rabbit
    List of antibodies used in the study
    Af909 Psd95 Mab Rabbit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/af909 psd95 mab rabbit/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    af909 psd95 mab rabbit - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    List of antibodies used in the study

    Journal: Brain

    Article Title: Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

    doi: 10.1093/brain/awz364

    Figure Lengend Snippet: List of antibodies used in the study

    Article Snippet: Negative controls were processed using the same protocol with the omission of the primary antibody to assess non-specific labelling. table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Source species Dilution Commercial source Catalogue # IHC, ICC Primary antibodies Arginase1 pAb Rabbit 1:100 Santa Cruz sc-20150 Beclin1 pAb Rabbit 1:100 Abcam ab16998 CD163 pAb Rabbit 1:100 Biorbyt Orb13303 CD204 mAb Scavenger R Type I/II (SCARA-1) Rat 1:100 AbD Serotec MCA1322 CD36 mAb clone MF3 Rat 1:200 Abcam ab80080 CD45 mAb clone 30-F11 Rat 1:25 BD Pharmingen #550539 EEA1 pAb Rabbit 1:100 Millipore 07-1820 GFAP mAb Rat 1:100 Invitrogen 13-0300 GFAP pAb Rabbit 1:100 Sigma-Aldrich G926 GFP pAb Rabbit 1:500 MBL #598 Human amyloid-β residues 17–24, mAb clone 4G8 Mouse 1:100 Covance/BioLegend 800711 Human amyloid-β residues 1–16, mAb clone 6E10 Mouse 1:100 Covance/BioLegend 803003 Iba1 pAb Rabbit 1:200 Wako Chemicals USA #019-19741 IGF1 pAb Goat 1:30 R&D systems AF791 iNOS mAb Rabbit 1:400 Cell Signaling 13120 Lamp1 mAb Rat 1:500 Abcam ab25245 Lamp2 mAb, clone M3/84 Rat 1:500 Millipore MABC24 MMP9 Goat 1:100 R&D systems AF909 PSD95 mAb Rabbit 1:600 Abcam ab76115 TREM2 pAb Goat 1:100 Abcam ab95470 VGluT1 pAb Guinea pig 1:6000 Millipore AB5905 Secondary antibodies Cy2 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Cy3 (anti-mouse, rat, rabbit, goat, guinea pig IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Cy5 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Flow cytometry CD11b mAb clone M1/70 (PE/Cy7) Rat 1 μl * eBioscience/ThermoFisher 25-0112-81 CD45 mAb clone 30-F11 (PE) Rat 1 μl * eBioscience/ThermoFisher 12-0451-81 F4/80 mAb clone BM8 (FITC) Rat 1 μl * eBioscience/ThermoFisher 11-4801-81 Human amyloid-β residues 1–16, mAb clone 6E10 Mouse 1:500 Covance/BioLegend 803003 IL10 mAb clone JES5-16E3 (PerCP-Cy5.5) Rat 1 μl * BioLegend 505028 Ly-6C mAb clone HK1.4 (eFluor450) Rat 1 μl * eBioscience/ThermoFisher 48-5932-80 TGFβ mAb clone TW7-16B4 (PerCP-Cy5.5) Mouse 1 μl * BioLegend 141410 TNFα mAb clone MP6-XT22 (APC) Rat 1 μl * BioLegend 506308 Open in a separate window mAb = monoclonal antibody; pAb = polyclonal antibody.

    Techniques: Flow Cytometry

    Cognitive preservation and restricted pathology following adoptive transfer of a CD115+ ACE10 monocyte subset in AD+ mice transgenic mice. (A–C) Schematic representation of experimental procedure and treatment groups. (A) CD115+ monocytes (MoBM) were isolated from the bone marrow of GFP+ donor mice and enriched by MACS microbeads and an anti-CD115 antibody column sorting procedure. (B) MoBM were then intravenously (i.v.) injected into the tail vein of AD+ recipient mice (n = 8 mice/group, all males). (C) Additional control groups included naïve wild-type (WT) mice and AD+ mice injected with PBS (n = 7 mice/group, all males). (D) Schematic timeline of the in vivo preclinical experiment. Pre-symptomatic AD+ mice exhibiting neuropathology at 8 months of age received monthly injections of 5–6 million GFP+MoWT or GFP+MoACE10 or PBS for 3 months (immunization regimen indicated by green arrows). At 11 months, mice underwent behavioural tests followed by tissue collection and analysis when 12 months of age. (E and F) Open field test in all AD+ treatment and naïve wild-type groups measuring: (E) ambulatory and (F) rearing activity. (G–K) Cognitive functions assessed by the Barnes maze test in both monocyte-treated groups as compared to the control PBS-injected group and naïve cognitively normal wild-type group (n = 6–8 mice/group). Incorrect entries (errors) for the following: (G) acquisition-training phase (Days 1–4), (H) memory retention (Day 7), (I) reversal phase (Days 8 or 9), and (J and K) memory test at Day 9. (J) Errors and (K) escape latency (s). (L) Quantitative IHC analysis of 6E10+ amyloid-β plaque areas in the hippocampus (HC), cingulate cortex (CC), and total brain in MoWT- and MoACE10-treated versus PBS-injected AD+ mice (n = 7–8 mice/group). (M) CAA score assessed as vascular Thio-S+ in AD+ mice (n = 6–8 mice/group). Data from an individual mouse as well as group mean ± SEM are shown. (N) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and postsynaptic (PSD95+) areas in MoACE10-treated mice compared to PBS-injected control AD+ and naïve wild-type mice (n = 6–8 mice/group). Data from individual mice, lower and upper quartiles (as lower and upper horizontal lines in box), median (midline within box), and minimum/maximum values (whiskers), are shown. Percentage increase and decrease compared to control groups are shown in green. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s post-test. Significance between two-groups by unpaired two-tailed Student t-test. IR = immunoreactive.

    Journal: Brain

    Article Title: Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

    doi: 10.1093/brain/awz364

    Figure Lengend Snippet: Cognitive preservation and restricted pathology following adoptive transfer of a CD115+ ACE10 monocyte subset in AD+ mice transgenic mice. (A–C) Schematic representation of experimental procedure and treatment groups. (A) CD115+ monocytes (MoBM) were isolated from the bone marrow of GFP+ donor mice and enriched by MACS microbeads and an anti-CD115 antibody column sorting procedure. (B) MoBM were then intravenously (i.v.) injected into the tail vein of AD+ recipient mice (n = 8 mice/group, all males). (C) Additional control groups included naïve wild-type (WT) mice and AD+ mice injected with PBS (n = 7 mice/group, all males). (D) Schematic timeline of the in vivo preclinical experiment. Pre-symptomatic AD+ mice exhibiting neuropathology at 8 months of age received monthly injections of 5–6 million GFP+MoWT or GFP+MoACE10 or PBS for 3 months (immunization regimen indicated by green arrows). At 11 months, mice underwent behavioural tests followed by tissue collection and analysis when 12 months of age. (E and F) Open field test in all AD+ treatment and naïve wild-type groups measuring: (E) ambulatory and (F) rearing activity. (G–K) Cognitive functions assessed by the Barnes maze test in both monocyte-treated groups as compared to the control PBS-injected group and naïve cognitively normal wild-type group (n = 6–8 mice/group). Incorrect entries (errors) for the following: (G) acquisition-training phase (Days 1–4), (H) memory retention (Day 7), (I) reversal phase (Days 8 or 9), and (J and K) memory test at Day 9. (J) Errors and (K) escape latency (s). (L) Quantitative IHC analysis of 6E10+ amyloid-β plaque areas in the hippocampus (HC), cingulate cortex (CC), and total brain in MoWT- and MoACE10-treated versus PBS-injected AD+ mice (n = 7–8 mice/group). (M) CAA score assessed as vascular Thio-S+ in AD+ mice (n = 6–8 mice/group). Data from an individual mouse as well as group mean ± SEM are shown. (N) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and postsynaptic (PSD95+) areas in MoACE10-treated mice compared to PBS-injected control AD+ and naïve wild-type mice (n = 6–8 mice/group). Data from individual mice, lower and upper quartiles (as lower and upper horizontal lines in box), median (midline within box), and minimum/maximum values (whiskers), are shown. Percentage increase and decrease compared to control groups are shown in green. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s post-test. Significance between two-groups by unpaired two-tailed Student t-test. IR = immunoreactive.

    Article Snippet: Negative controls were processed using the same protocol with the omission of the primary antibody to assess non-specific labelling. table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Source species Dilution Commercial source Catalogue # IHC, ICC Primary antibodies Arginase1 pAb Rabbit 1:100 Santa Cruz sc-20150 Beclin1 pAb Rabbit 1:100 Abcam ab16998 CD163 pAb Rabbit 1:100 Biorbyt Orb13303 CD204 mAb Scavenger R Type I/II (SCARA-1) Rat 1:100 AbD Serotec MCA1322 CD36 mAb clone MF3 Rat 1:200 Abcam ab80080 CD45 mAb clone 30-F11 Rat 1:25 BD Pharmingen #550539 EEA1 pAb Rabbit 1:100 Millipore 07-1820 GFAP mAb Rat 1:100 Invitrogen 13-0300 GFAP pAb Rabbit 1:100 Sigma-Aldrich G926 GFP pAb Rabbit 1:500 MBL #598 Human amyloid-β residues 17–24, mAb clone 4G8 Mouse 1:100 Covance/BioLegend 800711 Human amyloid-β residues 1–16, mAb clone 6E10 Mouse 1:100 Covance/BioLegend 803003 Iba1 pAb Rabbit 1:200 Wako Chemicals USA #019-19741 IGF1 pAb Goat 1:30 R&D systems AF791 iNOS mAb Rabbit 1:400 Cell Signaling 13120 Lamp1 mAb Rat 1:500 Abcam ab25245 Lamp2 mAb, clone M3/84 Rat 1:500 Millipore MABC24 MMP9 Goat 1:100 R&D systems AF909 PSD95 mAb Rabbit 1:600 Abcam ab76115 TREM2 pAb Goat 1:100 Abcam ab95470 VGluT1 pAb Guinea pig 1:6000 Millipore AB5905 Secondary antibodies Cy2 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Cy3 (anti-mouse, rat, rabbit, goat, guinea pig IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Cy5 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch Laboratories Flow cytometry CD11b mAb clone M1/70 (PE/Cy7) Rat 1 μl * eBioscience/ThermoFisher 25-0112-81 CD45 mAb clone 30-F11 (PE) Rat 1 μl * eBioscience/ThermoFisher 12-0451-81 F4/80 mAb clone BM8 (FITC) Rat 1 μl * eBioscience/ThermoFisher 11-4801-81 Human amyloid-β residues 1–16, mAb clone 6E10 Mouse 1:500 Covance/BioLegend 803003 IL10 mAb clone JES5-16E3 (PerCP-Cy5.5) Rat 1 μl * BioLegend 505028 Ly-6C mAb clone HK1.4 (eFluor450) Rat 1 μl * eBioscience/ThermoFisher 48-5932-80 TGFβ mAb clone TW7-16B4 (PerCP-Cy5.5) Mouse 1 μl * BioLegend 141410 TNFα mAb clone MP6-XT22 (APC) Rat 1 μl * BioLegend 506308 Open in a separate window mAb = monoclonal antibody; pAb = polyclonal antibody.

    Techniques: Preserving, Adoptive Transfer Assay, Transgenic Assay, Isolation, Injection, Control, In Vivo, Activity Assay, Two Tailed Test